Oncorus, Inc. is an early-stage biotechnology company developing an next-generation immunotherapy platform to treat cancer. Oncorus’s technology platform, based on innovative advancements with oncolytic viruses, has the potential to treat many tumor types, including highly malignant and aggressive cancers. Oncorus was founded by leading academic scientists and biotechnology entrepreneurs, including Mitchell H. Finer, PhD, an industry veteran and Managing Director of MPM Capital. A leader in corporate philanthropy, Oncorus has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world. Oncorus is headquartered in Kendall Square, Cambridge, Massachusetts.